Losartan and weight gain
Pro Research Analysisby 
Searched over 200M research papers
Losartan and Weight Gain: Insights from Recent Research
Introduction to Losartan and Weight Regulation
Losartan, an angiotensin II receptor blocker (ARB), is primarily used to manage hypertension. However, recent studies have explored its potential effects on body weight regulation, particularly in the context of diet-induced obesity (DIO). This article synthesizes findings from multiple research papers to provide a comprehensive understanding of how losartan influences weight gain.
Losartan's Impact on Weight Gain in Obesity-Prone Rats
Research has demonstrated that losartan can significantly affect weight gain in animals subjected to a high-fat diet. In a study involving diet-induced obese (DIO) rats, systemic AT1 receptor blockade with losartan (30 mg/kg/day) was shown to abolish body weight gain in both obesity-prone and obesity-resistant rats. Specifically, DIO rats experienced a reduction in daily weight gain from 3.6 ± 0.3 g/day to -0.4 ± 0.7 g/day, while diet-resistant rats saw a decrease from 2.1 ± 0.6 g/day to -0.8 ± 0.3 g/day 1. This effect was accompanied by a decrease in food intake, suggesting that losartan may help mitigate weight gain by reducing appetite in high-fat diet conditions.
Comparative Studies on Losartan and Weight Management
Another study reinforced these findings by showing that losartan administration prevented body weight gain in DIO rats. This study highlighted the role of the renin-angiotensin system (RAS) in energy homeostasis and suggested that interference with systemic RAS activity through losartan could decrease body weight and fat accumulation 2. These results align with the broader understanding that RAS plays a crucial role in regulating energy balance and body weight.
Losartan in Combination Therapies for Weight Management
In human studies, the combination of losartan with other medications has been explored for its potential to manage weight gain. A 12-month randomized trial compared the effects of rosiglitazone alone, rosiglitazone with metformin, and rosiglitazone with losartan in patients with nonalcoholic steatohepatitis (NASH). While the primary aim was to assess liver histopathology, the study also monitored weight changes. The results indicated no significant difference in weight gain mitigation between the treatment groups, suggesting that losartan's impact on weight might be more pronounced in specific contexts, such as high-fat diets, rather than in combination with other drugs for NASH 3.
Mechanisms Underlying Losartan's Effects on Weight
The mechanisms by which losartan influences weight gain are still being elucidated. One study on hypertensive rats indicated that losartan administration, particularly when combined with a low-sodium diet, could reduce body weight and blood pressure. This study suggested that losartan might affect weight through its impact on renal sodium and water excretion, as well as its interaction with the atrial natriuretic factor system 4.
Conclusion
Overall, the evidence suggests that losartan can play a significant role in preventing weight gain, particularly in the context of high-fat diets. Its effects appear to be mediated through mechanisms involving appetite reduction and possibly alterations in metabolic pathways related to the renin-angiotensin system. While more research is needed to fully understand these mechanisms and their implications for human health, losartan presents a promising avenue for managing weight gain in obesity-prone individuals.
Sources and full results
Most relevant research papers on this topic